Group 1 - Immuneering Corporation (NASDAQ:IMRX) is recognized as a promising fast money stock, with analysts at Mizuho maintaining an 'Outperform' rating and a price target of $10, indicating a potential increase of approximately 43% [1][2] - The company reported positive modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi) in first-line pancreatic cancer patients, with results from 34 patients showing overall survival and progression-free survival that exceeded both standard treatments and the firm's expectations [2][3] - The drug atebimetinib is highlighted for its potential to become a leading treatment for pancreatic cancer, with improved durability compared to previous data, reinforcing confidence in the drug's prospects and the company's future [3][4] Group 2 - Immuneering Corporation is a clinical-stage oncology company based in Massachusetts, founded in 2008, focused on developing innovative treatments for a wide range of cancer patients [4]

Core Points - The conference call is focused on the positive 9-month update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] - Key executives from Immuneering, including the CEO and Chief Scientific Officer, are present on the call to discuss the trial results and future plans [2] Company Updates - Immuneering is currently conducting a Phase IIa trial for atebemetinib, which is aimed at treating first-line pancreatic cancer patients [1][3] - The management team is expected to provide forward-looking statements regarding the trial and the timing of additional data [3][4]

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in our press rel ...

Core Viewpoint - Immuneering Corporation is actively pursuing financial strategies to enhance its position in the oncology market, despite recent stock volatility and a current price below its potential target. Group 1: Financial Activities - Immuneering announced an underwritten public offering of 18.96 million shares at $9.23 per share, aiming to raise approximately $175 million in gross proceeds [2][6] - The company has provided underwriters with a 30-day option to purchase an additional 2.84 million shares at the same offering price [3] - A $25 million private placement of Class A common stock has been arranged with Sanofi to support ongoing research and development efforts [3] Group 2: Stock Performance - The current stock price of Immuneering is $8, reflecting a decrease of approximately 13.33% from previous levels [4][6] - The stock has shown significant volatility, with a 52-week high of $10.08 and a low of $1.10 [4] - The market capitalization of Immuneering is approximately $290.42 million, with a trading volume of 13,719,027 shares for the day [5] Group 3: Analyst Insights - Jay Olson from Oppenheimer has set a price target of $30 for Immuneering, indicating a potential upside of about 25% from the current trading price [1][6]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but those who sign up for the yearly plan will be able to take advantage of a 33.50% dis ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - PepGen Inc. (PEPG) is up 151% at $6.68 [3] - 22nd Century Group, Inc. (XXII) is up 27% at $1.93 [3] - Immuneering Corporation (IMRX) is up 23% at $11.36 [3] - uniQure N.V. (QURE) is up 10% at $52.58 [3] - Lithium Americas Corp. (LAC) is up 9% at $6.60 [3] - Jasper Therapeutics, Inc. (JSPR) is up 9% at $2.55 [3] - American Shared Hospital Services (AMS) is up 8% at $2.75 [3] - PSQ Holdings, Inc. (PSQH) is up 7% at $3.06 [3] - K Wave Media Ltd. (KWM) is up 7% at $2.48 [3] - ClearPoint Neuro, Inc. (CLPT) is up 5% at $20.48 [3] Premarket Losers - Transocean Ltd. (RIG) is down 14% at $3.11 [4] - Cyclerion Therapeutics, Inc. (CYCN) is down 12% at $2.83 [4] - CarMax, Inc. (KMX) is down 11% at $50.38 [4] - ARB IOT Group Limited (ARBB) is down 11% at $10.45 [4] - SHF Holdings, Inc. (SHFS) is down 10% at $6.49 [4] - Digital Brands Group, Inc. (DBGI) is down 10% at $6.21 [4] - Aqua Metals, Inc. (AQMS) is down 9% at $5.29 [4] - Akanda Corp. (AKAN) is down 8% at $3.96 [4] - Galecto, Inc. (GLTO) is down 8% at $3.88 [4] - Platinum Analytics Cayman Limited (PLTS) is down 7% at $11.12 [4]

Core Points - Immuneering Corporation has priced its underwritten public offering of 18,959,914 shares of Class A common stock at $9.23 per share, with gross proceeds expected to be approximately $175 million before deductions [1][2] - Sanofi has agreed to purchase 2,708,559 shares of Immuneering's Class A common stock at the same price in a separate private placement transaction [1] - The public offering and private placement are expected to close concurrently on or about September 26, 2025, subject to customary closing conditions [1] Use of Proceeds - The net proceeds from the public offering and private placement will be used to advance the preclinical and clinical development of Immuneering's product candidates, as well as for working capital and other general corporate purposes [2] Offering Details - The public offering is made pursuant to a shelf registration statement on Form S-3, which was filed with the SEC on August 13, 2025, and declared effective on August 20, 2025 [3] - A prospectus supplement relating to the offering will be filed with the SEC [3] Private Placement - The shares sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the U.S. without registration or an applicable exemption [4]

Core Viewpoint - Immuneering Corporation has announced a proposed underwritten public offering of its Class A common stock and a concurrent private placement with Sanofi for $25 million, aimed at advancing its oncology product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes shares of Class A common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase an additional 15% of the offered shares [1]. - Sanofi will purchase $25 million worth of Immuneering's Class A common stock or non-voting Class B common stock at the public offering price, in a private placement expected to close concurrently with the public offering [1][2]. - The offering is subject to market conditions and the private placement is contingent upon the closing of the public offering [1]. Group 2: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to advance preclinical and clinical development of product candidates, as well as for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on August 20, 2025 [3]. - A preliminary prospectus supplement will be filed with the SEC, and copies will be available through the underwriters [3][7]. Group 4: Securities Registration - The shares sold in the private placement will not be registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].

Core Insights - Immuneering Corporation announced positive survival and safety data from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients, showing an overall survival (OS) of 86% at 9 months, significantly higher than the standard of care benchmark of approximately 47% [1][6][10] Survival Data - The trial reported a 94% OS at 6 months, which was sustained to 86% at 9 months, indicating a substantial improvement over standard care [2][6] - Progression-free survival (PFS) was observed at 53% at 9 months, compared to a standard of care benchmark of around 29% [5][6] Safety Profile - The combination therapy demonstrated a favorable tolerability profile, with only neutropenia and anemia observed at Grade 3 in more than 10% of patients, which are common in standard chemotherapy [10][11] - No new safety signals were identified, reinforcing the treatment's tolerability [10] Mechanism of Action - Atebimetinib is classified as a Deep Cyclic Inhibitor, targeting MEK, which is a key control point in the MAPK pathway, potentially offering a more durable treatment option for pancreatic cancer [12][13] Future Plans - The company anticipates regulatory feedback on pivotal trial plans in Q4 2025 and aims to initiate a pivotal trial by the end of 2025, with patient dosing expected to begin by mid-2026 [5][18] - Immuneering is also planning to expand clinical trials for atebimetinib in other cancer types, including non-small cell lung cancer [18]

Core Viewpoint - Immuneering Corporation has appointed Dr. Thomas J. Schall as Chairman of the Board of Directors, which is seen as a strategic move to advance the company's oncology programs, particularly the lead product candidate, atebimetinib [1][4]. Company Overview - Immuneering is a clinical-stage oncology company focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors. The lead product candidate, atebimetinib, is designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [5]. Leadership Background - Dr. Schall has over 30 years of experience in drug discovery and development, previously serving as the founder and CEO of ChemoCentryx, where he led the development of Tavneos®, a therapy for ANCA-associated vasculitis. ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion [2][4]. Strategic Importance - The appointment of Dr. Schall is considered pivotal as Immuneering prepares for late-stage development, regulatory filings, and commercialization of its therapies. His expertise in navigating the complex path from early science to market is expected to be critical for the company's success [3][4]. Upcoming Developments - Immuneering plans to announce updated data from its ongoing phase 2a study of atebimetinib in pancreatic cancer patients on September 25, with further presentations at the Pancreatic Cancer Action Network Annual Scientific Summit on September 28 [3].